Alzheimer’s disease (AD) is a progressive multifactorial neurodegenerative disorder.
Currently, no effective treatment is available and this is due to multiple factors involved
in pathophysiology and severity of AD. A recent approach for the rational design of new drug
candidates, also called multitarget-directed ligands (MTDL) strategy, has been used to develop
a variety of hybrid compounds capable to act simultaneously in diverse biological targets.
The discovery of drug candidates capable of targeting multiple factors involved in AD
pathogenesis would greatly facilitate in improving therapeutic strategies. This review is a
complement to another review article, recently published by our group, which covered the
previous period of 2005-2012, and highlights recent advances and examples of the exploitation
of MTDLs approach in the rational design of novel drug candidate prototypes for the
treatment of AD.
Keywords: Alzheimer`s disease, multi-target directed drugs, rational drug design, multifunctional drugs, multitarget
drugs, neurodegenerative diseases, MTDLs.
Rights & PermissionsPrintExport